意大利多中心III期随机研究:顺铂联合依托泊苷联合或不联合贝伐珠单抗一线治疗广泛期小细胞肺癌:GOIRC-AIFA FARM6PMFJM试验
本研究为意大利多中心III期随机试验,纳入204例初治广泛期小细胞肺癌患者,随机接受顺铂联合依托泊苷(A组)或联合贝伐珠单抗(B组)。结果显示,B组较A组无进展生存期显著改善,但总生存期无显著差异,且B组3或4级高血压更常见。
要点
- B组较A组无进展生存期中位改善1个月(5.7 vs 6.7个月,P=.030)。
- B组较A组总生存期无显著差异(中位8.9 vs 9.8个月,HR 0.78,P=.113)。
- B组较A组3或4级高血压更常见(1.0% vs 6.3%,P=.057)。
核心结论
- 在广泛期小细胞肺癌一线治疗中,顺铂联合依托泊苷基础上加用贝伐珠单抗毒性可接受,无进展生存期显著改善,但总生存期无显著改善。
- 作者认为需进一步研究新型抗血管生成药物,尤其在维持治疗阶段。
研究设计与样本
- 意大利多中心III期随机试验,纳入204例初治广泛期小细胞肺癌患者,随机分入A组(顺铂联合依托泊苷,103例)或B组(同方案联合贝伐珠单抗,101例),最多6个疗程;B组无进展者继续贝伐珠单抗单药维持至疾病进展或最多18个疗程。
- 主要终点为总生存期。
主要发现
- 中位随访34.9个月时,A组与B组中位总生存期分别为8.9个月和9.8个月,1年生存率分别为25%和37%(HR 0.78,95%CI 0.58至1.06,P=.113)。
- 接受维持治疗的患者中,贝伐珠单抗对总生存期有统计学显著影响(HR 0.60,95%CI 0.40至0.91,P=.011)。
- A组与B组中位无进展生存期分别为5.7个月和6.7个月(P=.030)。
- 血液学毒性无统计学显著差异;非血液学毒性中仅高血压在B组更常见(3或4级,A组1.0% vs B组6.3%,P=.057)。
关键数值与推荐
- 无进展生存期:A组5.7个月 vs B组6.7个月(P=.030)。
- 总生存期:A组8.9个月 vs B组9.8个月(HR 0.78,95%CI 0.58至1.06,P=.113)。
- 接受维持治疗者总生存期:HR 0.60(95%CI 0.40至0.91,P=.011)。
- 3或4级高血压:A组1.0% vs B组6.3%(P=.057)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Considering promising results in phase II studies, a randomized phase III trial was designed to assess the efficacy of adding bevacizumab to first-line cisplatin plus etoposide for treatment of extensive-disease (ED) small-cell lung cancer (SCLC). Patients and Methods Treatment-naive patients with ED-SCLC were randomly assigned to receive either cisplatin plus etoposide (arm A) or the same regimen with bevacizumab (arm B) for a maximum of six courses. In the absence of progression, patients in arm B continued bevacizumab alone until disease progression or for a maximum of 18 courses. The primary end point was overall survival (OS). Results Two hundred four patients were randomly assigned and considered in intent-to-treat analyses (103 patients in arm A and 101 patients in arm B). At a median follow-up of 34.9 months in arm A and arm B, median OS times were 8.9 and 9.8 months, and 1-year survival rates were 25% and 37% (hazard ratio, 0.78; 95% CI, 0.58 to 1.06; P = .113), respectively. A statistically significant effect of bevacizumab on OS in patients who received maintenance was seen (hazard ratio, 0.60; 95% CI, 0.40 to 0.91; P = .011). Median progression-free survival times were 5.7 and 6.7 months in arm A and arm B, respectively ( P = .030). Regarding hematologic toxicity, no statistically significant differences were observed; for nonhematologic toxicity, only hypertension was more frequent in arm B (grade 3 or 4, 1.0% v 6.3% in arms A v B, respectively; P = .057). Conclusion The addition of bevacizumab to cisplatin and etoposide in the first-line treatment of ED-SCLC had an acceptable toxicity profile and led to a statistically significant improvement in progression-free survival, which, however, did not translate into a statistically significant increase in OS. Further research with novel antiangiogenic agents, particularly in the maintenance setting, is warranted.
引用
- Tiseo M, Boni L, Ambrosio F, et al. Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. J Clin Oncol. 2017. PMID: 28135143. doi:10.1200/JCO.2016.69.4844
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。